| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
in00005772849 |
| 005 |
20260327175525.7 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
240211s2024 enka ob 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d OCLCO
|d UKAHL
|d N$T
|d OCLCQ
|d OCLCL
|d SFB
|d VTM
|
| 019 |
|
|
|a 1555349053
|
| 020 |
|
|
|a 9780323956734
|q (electronic bk.)
|
| 020 |
|
|
|a 0323956734
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323956727
|
| 020 |
|
|
|z 0323956726
|
| 035 |
|
|
|a (OCoLC)1420601504
|z (OCoLC)1555349053
|
| 050 |
|
4 |
|a RC394.H85
|b H86 2024
|
| 060 |
|
4 |
|a WL 359.5
|
| 082 |
0 |
4 |
|a 616.85/1
|2 23/eng/20240226
|
| 049 |
|
|
|a TXAM
|
| 130 |
0 |
|
|a Huntington's disease (Yang)
|
| 245 |
0 |
0 |
|a Huntington's disease :
|b pathogenic mechanisms and implications for therapeutics /
|c edited by X. William Yang, Leslie M. Thompson, Myriam Heiman.
|
| 264 |
|
1 |
|a London :
|b Academic Press,
|c 2024.
|
| 300 |
|
|
|a 1 online resource (xix, 597 pages :
|b illustrations (chiefly color)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 505 |
0 |
|
|a Intro -- Title page -- Table of Contents -- Copyright -- Dedication -- Contributors -- Preface -- Chapter 1. Huntington's disease: Clinical features, genetic diagnosis, and brain imaging -- Introduction -- Clinical course -- Juvenile Huntington's disease -- Genetic diagnosis and genetic counseling -- Imaging -- Conclusion: Clinical aspects relevant for the development of disease-modifying therapies in Huntington's disease -- List of abbreviations -- Chapter 2. Revolutionizing clinical research and communication in Huntington's disease: The Huntington's disease integrated staging system (HD-ISS) -- Introduction -- Disease classification, measurement, and staging -- The development of the HD-ISS -- Applying the HD-ISS in research: New possibilities -- Applying the HD-ISS in research: Practical questions -- Applying the HD-ISS in research: Implications for people with Huntington's disease -- Conclusion -- Chapter 3. Huntington's disease genetics: Implications for pathogenesis -- Description of inheritance -- Chromosomal mapping of the HD genetic defect and its consequences -- The HD genetic defect -- The expanded HTT CAG repeat confers a gain of function -- HD genotype-phenotype correlation -- Modifiers of HD onset from human genetics -- A model for HD pathogenesis from human genetics -- Underpinnings of the modifier effects -- Modifiers of other disease landmarks -- HD diagnostics -- What is the ultimate cause of neuronal loss? -- Potential for developing an HD treatment from genetic knowledge -- Conclusion -- Chapter 4. The instability of the Huntington's disease CAG repeat mutation -- Introduction: The critical role of CAG repeat length -- Intergenerational repeat instability -- Somatic repeat instability -- Insights into CAG repeat instability from mouse models -- Insights from human genetics -- Conclusions and perspective.
|
| 505 |
8 |
|
|a Chapter 5. Mechanisms of somatic CAG-repeat expansions in Huntington's disease -- Introduction -- Current understanding of somatic repeat instability -- Slip-out formation -- Requirement of transcription and transcription-coupled repair for somatic repeat instability -- Melting unusual structures at the repeat and modulating torsional tension -- Many nucleases can act on slipped-DNA structures which may impact repeat instability -- Gap-filling and ligation of the DNA backbone -- What is still unclear? -- Conclusion -- Chapter 6. RNA-mediated pathogenic mechanisms in Huntington's disease -- Expression of the huntingtin gene -- Regulation of huntingtin transcription -- Alternative processing of huntingtin pre-mRNA -- Nuclear RNA "clusters" and RNA "foci" in HD mouse models and HD patient samples -- Global aberrant RNA processing in HD -- RNA-based mechanism of pathogenesis -- Implications for therapy -- Chapter 7. Huntingtin protein-protein interactions: From biology to therapeutic targets -- Introduction -- Two-hybrid HTT protein interaction mapping efforts -- Cataloging of HTT interacting partners using (immuno)affinity-based purification approaches -- Compilation and computational analysis of HTT PPIs from large- and small-scale PPI mapping studies -- Outlook -- Chapter 8. Repeat-associated non-AUG (RAN) translation and Huntington's disease: Pathology, mechanistic and therapeutic perspectives -- Introduction to RAN translation -- RAN proteins in Huntington's disease -- RAN and polyGln proteins accumulate in distinct and vulnerable brain regions -- Animal models of HD and RAN translation -- RAN protein toxicity -- Mechanistic focused therapeutics -- Conclusions -- Chapter 9. Proteostasis function and dysfunction in Huntington's disease -- Introduction -- Impact of mHTT protein on HD pathology and protein aggregation propensity.
|
| 505 |
8 |
|
|a Therapeutic opportunities -- Conclusion and future directions -- Chapter 13. Pathophysiology of synapses and circuits in Huntington disease -- Clinical and genetic features of HD -- Cortical-basal ganglia-thalamic-cortical loops regulate movement and are modulated by dopamine -- Neuropathology -- Measurable subclinical changes precede definitive motor diagnosis -- Animal models of HD facilitate investigating brain changes before overt clinical diagnosis -- Striatal microcircuit synapses -- Synaptic alterations in basal ganglia nuclei downstream of striatal SPN -- Neuronal excitability -- Input-specific plasticity: Long-term potentiation and depression -- Homeostatic plasticity -- Altered corticostriatal and thalamostriatal connectivity in HD -- Cortex motor and sensory function -- Cortex reward pathways -- Targeting synaptic and circuit changes to advance therapeutics in Huntington disease -- Chapter 14. The role of glial pathology in Huntington's disease -- The role of glial progenitor cells in HD pathogenesis -- Astrocytic dysfunction in HD -- The effects of HD pathology on oligodendrocytes and myelin -- Synopsis -- Chapter 15. Systems biology study of Huntington's disease -- Introduction -- Transcriptomic profiling of HD mice -- Insights from transcriptomic studies of HD mouse models -- Mechanisms implicated in striatal transcriptinopathy in HD -- Epigenomic dysregulation in HD mice -- Application of systems biology to study HD perturbations -- Database of HD experimental data -- Conclusions and perspectives -- Chapter 16. Unbiased genome-wide approaches to identify vulnerability factors in Huntington's disease -- Yeast model screening studies -- Invertebrate model screening studies -- Mammalian cell screening studies -- Mammalian in vivo screening -- Future directions.
|
| 505 |
8 |
|
|a Chapter 17. Striatal neuronal models of Huntington's disease via direct conversion: Modeling age-dependent disease phenotypes -- MicroRNA-mediated conversion of human fibroblasts to neurons -- Age maintenance in directly reprogrammed neurons -- Recapitulation of adult-onset neuropathology of Huntington's disease using miRNAs-mediated reprogrammed neurons -- Modeling disease-stage progression of Huntington's disease -- Conclusion -- Chapter 18. Genetic mouse models to explore Huntington's disease mechanisms and therapeutic strategies -- Transgenic mHTT N-terminal fragment mouse models of HD -- Full-length mHTT knock-in mouse models -- Full-length human HTT transgenic models -- Conclusions and perspectives -- Chapter 19. Huntington's disease: From large animal models to HD gene therapy -- Introduction to Huntington's disease neuropathology -- Treatment of large animal models of HD -- Conclusions -- Chapter 20. Deep learning and deep phenotyping of HD iPSCs: Applications to study biology and test therapeutics -- Background: Complexity in biology -- A brief introduction to AI -- Applications of DL to biology -- Impact -- Chapter 21. The promise of an underappreciated therapeutic target: Sleep and circadian rhythm dysfunction in Huntington's disease -- Sleep disturbance in Huntington's disease: The evidence -- Sleep disturbance in Huntington's disease: Preclinical models -- Which comes first, HD or sleep dysfunction, and does it matter? -- Circadian-based interventions in preclinical models -- Pharmacological interventions -- Conclusions -- Chapter 22. Huntingtin lowering therapeutics -- DNA oligonucleotides -- Oligonucleotides that use RNA interference -- siRNA oligonucleotides as therapeutic agents in HD -- Gene editing to lower or correct mutant huntingtin mRNA or protein -- AAV gene delivery for Huntington's disease: Background.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on print version record.
|
| 520 |
|
|
|a Huntington's disease (HD) is one of the most common dominantly inherited neurodegenerative disorders, characterized by a clinical trial of movement disorder, cognitive deficits, and psychiatric symptoms.
|
| 650 |
|
0 |
|a Huntington's disease.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Yang, X. William,
|e editor.
|
| 700 |
1 |
|
|a Thompson, Leslie M.
|c (Professor),
|e editor.
|
| 700 |
1 |
|
|a Heiman, Myriam,
|e editor.
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 776 |
0 |
8 |
|i Print version:
|z 0323956726
|z 9780323956727
|w (OCoLC)1402021467
|
| 776 |
0 |
8 |
|z 0-323-95672-6
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/book/9780323956727
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i 254d222a-be43-48c4-9c85-052cd8d1f2ef
|s b13ae9e8-99ed-49b0-9da8-8ab0e528e3ba
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RC394.H85 H86 2024
|h Library of Congress classification
|
| 998 |
f |
f |
|a RC394.H85 H86 2024
|t 0
|l Available Online
|